Financials data is unavailable for this security.
View more
Year on year Consun Pharmaceutical Group Ltd grew revenues 10.71% from 2.34bn to 2.59bn while net income improved 14.88% from 682.91m to 784.53m.
| Gross margin | 74.22% |
|---|---|
| Net profit margin | 30.66% |
| Operating margin | 34.59% |
| Return on assets | 15.97% |
|---|---|
| Return on equity | 23.91% |
| Return on investment | 23.24% |
More ▼
Cash flow in CNYView more
In 2023, Consun Pharmaceutical Group Ltd increased its cash reserves by 12.17%, or 298.09m. The company earned 818.97m from its operations for a Cash Flow Margin of 31.62%. In addition the company used 231.77m on investing activities and also paid 280.10m in financing cash flows.
| Cash flow per share | 1.25 |
|---|---|
| Price/Cash flow per share | 5.05 |
| Book value per share | 4.82 |
|---|---|
| Tangible book value per share | 4.47 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.06 |
|---|---|
| Quick ratio | 2.80 |
| Total debt/total equity | 0.1393 |
|---|---|
| Total debt/total capital | 0.1144 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 54.38% and 13.85%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 7.43% |
|---|---|
| Div growth rate (5 year) | 18.43% |
| Payout ratio (TTM) | 26.44% |
| EPS growth(5 years) | 13.12 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 12.05 |
More ▼
